



an Open Access Journal by MDPI

The Use of Epigenetic Biomarkers as Diagnostic and Therapeutic Options 2.0

Guest Editor:

Dr. Yuen Yee Cheng

Institute for Biomedical Materials and Devices, University of Technology Sydney, 15 Broadway, Ultimo, NSW 2007, Australia

Deadline for manuscript submissions:

closed (30 April 2022)

Message from the Guest Editor

The present Special Issue aims to publish high-quality research articles as well as review contributions on a variety of topics related to epigenetic biomarkers, COVID-19, and therapeutic options.

Potential topics include, but are not limited to:

- Types of epigenetic biomarkers used in clinical practice for different diseases:
 - DNA methylation of circulating or non-circulating DNA;
 - Histone modification (e.g., histone methylation and acetylation);
 - microRNA, circular RNA, and other non-coding RNA;
- Methods of new epigenetic biomarker discovery;
- The potential of liquid biopsy for epigenetic biomarker detection;
- The process of developing of epigenetic biomarkers as treatment options for clinical practice.



mdpi.com/si/78373



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at
Mount Sinai, Hess Center for
Science and Medicine, New York,
NY 10029, USA

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [ESCI \(Web of Science\)](#), [PMC](#), [PubMed](#), [Embase](#), [PubAg](#), [CAPlus / SciFinder](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*Biochemistry, Genetics and Molecular Biology (miscellaneous)*)

Contact Us

Epigenomes Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/epigenomes
epigenomes@mdpi.com
[X@Epigenomes](#)